Ozone Therapy for Cancer Therapy-Related Oral Mucositis (OMUC-O3)
Retrospective Evaluation of Combined Chairside and Domiciliary Ozone Therapy for the Management of Cancer Therapy-Related Oral Mucositis
This retrospective observational study will evaluate clinical data already available from adult cancer patients who developed cancer therapy-related oral mucositis during radiotherapy and/or chemotherapy and who were managed in routine clinical practice with combined chairside and domiciliary ozone therapy.
The study will not assign participants to any treatment and will not involve any new intervention, visit, examination, or change in patient care. Data will be extracted from existing medical records and clinical documentation.
The main purpose of the study is to describe the clinical course of oral mucositis and to evaluate the time needed to reach oral mucositis grade 1 or lower according to the World Health Organization Oral Toxicity Scale. The study will also assess changes in oral pain intensity, measured using a 0 to 10 Visual Analogue Scale, from baseline to follow-up visits up to 15 days.
Exploratory analyses will compare clinical trends between patients with head and neck cancers and patients with cancers in other anatomical sites. The results will be interpreted as descriptive and exploratory because the study is retrospective, single-arm, and has no control group.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Oral mucositis is a clinically relevant complication of anticancer treatments, especially radiotherapy and chemotherapy. It can cause erythema, ulcerations, oral pain, dysphagia, impaired oral intake, and reduced quality of life. In routine clinical practice, selected patients with cancer therapy-related oral mucositis were managed with a combined ozone-based protocol including professional chairside ozone application and domiciliary ozonized oral care products.
This study is designed as a retrospective observational analysis of data already available from medical records and clinical documentation. No prospective enrollment, treatment allocation, randomization, study-specific intervention, biological sampling, imaging, or additional clinical visit will be performed.
The study will include adult oncological patients with documented cancer therapy-related oral mucositis grade 1 or higher according to the World Health Organization Oral Toxicity Scale. Available data will include demographic and clinical information, oncological disease site, oral mucositis severity, and oral pain intensity measured using a 0 to 10 Visual Analogue Scale.
The retrospective observation period includes clinical data collected during routine care between November 2023 and September 2025. Outcome data will be analyzed from baseline to available follow-up visits up to 15 days. Additional exploratory analyses will describe clinical trends according to cancer site, comparing patients with head and neck cancers with patients with malignancies in other anatomical sites.
The findings will be interpreted as descriptive and exploratory, because the study is retrospective, single-arm, and does not include a control group.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Lombardy
-
Pavia, Lombardy, Italia, 27100
- Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Age 18 years or older
- Oncological patients undergoing radiotherapy and/or chemotherapy
- Clinical diagnosis of cancer therapy-related oral mucositis grade 1 or higher according to the World Health Organization Oral Toxicity Scale
- Availability of clinical documentation including World Health Organization Oral Toxicity Scale assessments and Visual Analogue Scale pain scores at baseline and at one or more follow-up timepoints
- Availability of relevant demographic and clinical information required for the retrospective analysis
Exclusion Criteria:
- Age younger than 18 years
- Absence of a documented diagnosis of cancer therapy-related oral mucositis
- Incomplete or unavailable clinical documentation for the primary and/or main secondary outcome
- Missing baseline World Health Organization Oral Toxicity Scale assessment
- Missing baseline Visual Analogue Scale pain assessment
- Any condition making the available data unsuitable for retrospective analysis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Cancer Therapy-Related Oral Mucositis Cohort
Adult oncological patients with documented cancer therapy-related oral mucositis grade 1 or higher according to the World Health Organization Oral Toxicity Scale.
Patients were previously managed in routine clinical practice with a combined ozone-based protocol including professional chairside ozone application and domiciliary ozonized oral care products.
This is a retrospective observational cohort; no treatment assignment, randomization, or study-specific intervention will be performed.
|
Adult oncological patients with cancer therapy-related oral mucositis were previously managed in routine clinical practice with a combined ozone-based oral care protocol.
The protocol included professional chairside ozone application to oral mucosal lesions using an ozone device with a mucosa-specific probe, followed by domiciliary use of ozonized oral care products, including ozonized hydrogel, toothpaste, and mouthwash, according to routine clinical instructions.
In this retrospective observational study, no intervention will be assigned or performed for research purposes, and no change to patient management is planned.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Achieve Oral Mucositis Grade 1 or Lower
Periodo de tiempo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Time, expressed in days, required to achieve oral mucositis grade 1 or lower according to the World Health Organization Oral Toxicity Scale.
The outcome will be assessed retrospectively using clinical data already available from medical records and clinical documentation.
Patients who did not reach WHO grade 1 or lower by the last available follow-up will be censored at their last valid assessment.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Oral Pain Intensity
Periodo de tiempo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Absolute change in oral pain intensity from baseline to the end of follow-up, assessed using a Visual Analogue Scale from 0 to 10, where higher scores indicate greater pain intensity.
The outcome will be assessed retrospectively using clinical data already available from medical records and clinical documentation.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Change in Oral Mucositis Severity Over Time
Periodo de tiempo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Change in oral mucositis severity across the available follow-up timepoints, assessed using the World Health Organization Oral Toxicity Scale.
Scores will be extracted retrospectively from existing clinical documentation at baseline and follow-up visits.
Lower scores indicate lower oral mucositis severity.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Change in Oral Pain Intensity Over Time
Periodo de tiempo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Change in oral pain intensity across the available follow-up timepoints, assessed using a Visual Analogue Scale from 0 to 10. Scores will be extracted retrospectively from existing clinical documentation at baseline and follow-up visits.
Higher scores indicate greater pain intensity.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Oral Mucositis Severity Trends by Cancer Site
Periodo de tiempo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Exploratory comparison of oral mucositis severity trends between patients with head and neck cancers and patients with malignancies in other anatomical sites, assessed using the World Health Organization Oral Toxicity Scale across the available retrospective follow-up timepoints.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
|
Oral Pain Intensity Trends by Cancer Site
Periodo de tiempo: At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Exploratory comparison of oral pain intensity trends between patients with head and neck cancers and patients with malignancies in other anatomical sites, assessed using a Visual Analogue Scale from 0 to 10 across the available retrospective follow-up timepoints.
Higher scores indicate greater pain intensity.
|
At baseline before ozone therapy (T0), immediately after the first professional ozone application (T1), 48 hours after T1 (T2), 5 days after T1 (T3), 8 days after T1 (T4), 12 days after T1 (T5), and 15 days after T1 (T6)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2026-OMUC-O3
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .